Literature DB >> 28934460

Commentary: A Historical Review of Centers for Disease Control and Prevention Antiviral Treatment and Postexposure Chemoprophylaxis Guidance for Human Infections With Novel Influenza A Viruses Associated With Severe Human Disease.

Fiona P Havers1, Angela P Campbell1, Timothy M Uyeki1, Alicia M Fry1.   

Abstract

Human infections with novel influenza A viruses are of global public health concern, and antiviral medications have a potentially important role in treatment and prevention of human illness. Initial guidance was developed by the U.S. Centers for Disease Control and Prevention after the emergence of human infections with avian influenza A(H5N1) and has evolved over time, with identification of influenza A(H7N9) virus infections in humans, as well as detection of avian influenza viruses in birds in the United States. This commentary describes the historical context and current guidance for the use of influenza antiviral medications for treatment and post-exposure chemoprophylaxis of human infections with novel influenza A viruses associated with severe human illness, or with the potential to cause severe human disease, and provides the scientific rationale behind current recommendations. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  antiviral treatment; avian influenza; neuraminidase inhibitors

Mesh:

Substances:

Year:  2017        PMID: 28934460     DOI: 10.1093/infdis/jix065

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  2 in total

1.  The Global Threat of Animal Influenza Viruses of Zoonotic Concern: Then and Now.

Authors:  Marc-Alain Widdowson; Joseph S Bresee; Daniel B Jernigan
Journal:  J Infect Dis       Date:  2017-09-15       Impact factor: 5.226

2.  Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.

Authors:  Zsolt Szűcs; Viktor Kelemen; Son Le Thai; Magdolna Csávás; Erzsébet Rőth; Gyula Batta; Annelies Stevaert; Evelien Vanderlinden; Lieve Naesens; Pál Herczegh; Anikó Borbás
Journal:  Eur J Med Chem       Date:  2018-08-22       Impact factor: 6.514

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.